Vaccitech to Present at the Barclays Global Healthcare Conference 2022

Rhea-AI Summary

Vaccitech plc (NASDAQ: VACC) announced participation in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 2:05 p.m. EDT, featuring CEO Bill Enright and CFO Georgy Egorov in Miami. The webcast will be available live and later as a replay on the company's website. Vaccitech focuses on developing immunotherapies for chronic infectious diseases and cancer using proprietary platforms, including modified viral vectors. The company co-invented a COVID-19 vaccine with the University of Oxford, licensed to AstraZeneca.

OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Barclays Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15, 2022, in Miami.

A live webcast of the presentation can be accessed through the Events section of the Vaccitech website. Following the live webcast, a replay will be available at the same location.

About Vaccitech plc
Vaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment of chronic infectious diseases, cancer and diseases where the T cell arm of the immune system is believed to play an important role. The company’s proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections, as well as a few prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com

Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc. (U.S.)
Email: klarch@burnsmc.com / rflamm@burnsmc.com

Karim Saleh, Vaccitech
Email: karim.saleh@vaccitech.co.uk

FAQ

What is Vaccitech's participation in the Barclays Global Healthcare Conference?

Vaccitech's CEO and CFO will participate in a fireside chat at 2:05 p.m. EDT on March 15, 2022.

Where can I watch Vaccitech's presentation at the Barclays Conference?

The presentation will be available via live webcast on Vaccitech's website, with a replay after.

What technologies does Vaccitech use in its immunotherapies?

Vaccitech utilizes modified viral vectors, including ChAdOx1 and ChAdOx2, for its immunotherapy development.

What notable vaccine did Vaccitech co-invent?

Vaccitech co-invented a COVID-19 vaccine with the University of Oxford.

What is the stock symbol for Vaccitech?

Vaccitech is traded under the stock symbol VACC on NASDAQ.